Clinical features and prognosis for anaplastic large cell lymphoma.
10.11817/j.issn.1672-7347.2018.06.009
- Author:
Fei DONG
1
;
Yan LIU
1
;
Qihui LI
1
;
Jijun WANG
1
;
Hongmei JING
1
;
Xiaoyan KE
1
Author Information
1. Department of Hematology, Peking University Third Hospital, Beijing 100191, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Age Factors;
Aged;
Alkaline Phosphatase;
Antineoplastic Combined Chemotherapy Protocols;
administration & dosage;
therapeutic use;
Bleomycin;
administration & dosage;
Child;
Cyclophosphamide;
administration & dosage;
Doxorubicin;
administration & dosage;
Etoposide;
administration & dosage;
Female;
Humans;
Lymphoma, Large-Cell, Anaplastic;
drug therapy;
enzymology;
mortality;
Male;
Middle Aged;
Prednisone;
administration & dosage;
Prognosis;
Retrospective Studies;
Sex Factors;
Treatment Outcome;
Vincristine;
administration & dosage;
Young Adult
- From:
Journal of Central South University(Medical Sciences)
2018;43(6):631-637
- CountryChina
- Language:Chinese
-
Abstract:
To determine clinical and pathologic profiles for anaplastic large cell lymphoma (ALCL).
Methods: The clinical data of 22 patients with ALCL were analyzed retrospectively. Therapentie effect of different treatment strategies on ALCL was evaluated.
Results: The median age for these patients was 32(9-70) years old and the patients with positive ALK accounted for 68.2% (15/22). All patients underwent chemotherapy, including regiments of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), CHOPE (CHOP plus etoposide) or BEACOP (CHOP plus etoposide and bleomycin). Fourteen (63.6%) patients achieved initial complete remission (CR) and the CR rate for patients with ALK+ was significantly higher than that of patients with ALK- (P<0.05), while the age, gender, stage, beta 2-microglobulin (2-MG) level, lactate dehydrogenase (LDH) level, B symptoms had no significant effect on the rate of CR (P>0.05). After a median follow-up of 41 (2-150) months, 12 patients were overall survival, the median progression free time was 22.5 (2-150) months, and the age, gender, stage, IPI index, ALK expression level, beta 2-MG level, LDH level, and B symptoms had no significant effect on the rate of overall survival (P>0.05).
Conclusion: ALK-positive occurs mainly in ALCL patients. The chemotherapy is still the main treatment, and CHOPE regimen is a better initial treatment scheme because the most patients show good prognosis.
